AtriCure, Inc. (ATRC) stock
Close on Nov 17, 2026Market cap $2.80BP/E 262.0Yield –
Earnings
AtriCure's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of AtriCure's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 16, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026after the close | $154.50M | +15.0% | $0.08 | $0.18 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 23, 2026after the close | $153.60M | +12.9% | $0.18 | $0.18 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026after the close | $141.20M | +14.2% | $0.00 | $0.00 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 17, 2026after the close | $140.50M | +13.0% | $0.04 | $0.06 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025after the close | $134.30M | +15.9% | -$0.01 | -$0.01 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 29, 2025after the close | $136.10M | +17.0% | -$0.13 | -$0.02 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 29, 2025after the close | $123.60M | +13.5% | -$0.14 | -$0.14 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 12, 2025after the close | $124.30M | +16.7% | $0.33 | $0.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 29, 2024after the close | $115.90M | +17.9% | -$0.17 | -$0.17 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 30, 2024after the close | $116.30M | +15.3% | $0.17 | $0.17 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 1, 2024after the close | $108.90M | +16.5% | $0.28 | $0.25 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 15, 2024after the close | $106.50M | +21.0% | $0.21 | $0.21 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023after the close | $98.30M | +18.1% | $0.20 | $0.20 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 25, 2023after the close | $100.90M | +19.4% | $0.11 | $0.12 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 2, 2023after the close | $93.50M | +25.3% | $0.14 | $0.23 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 21, 2023after the close | $88.00M | +20.2% | $0.09 | $0.09 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 1, 2022after the close | $83.20M | +18.0% | $0.27 | $0.27 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022after the close | $84.50M | – | $0.32 | $0.32 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022after the close | $74.60M | – | $0.33 | $0.33 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 15, 2022after the close | $73.20M | – | $0.30 | $0.30 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021after the close | $70.50M | – | $2.11 | $0.23 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 27, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 23, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
AtriCure's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenueGAAP | FY2026 | $606.00M – $610.00M | – | New | Nov 3, 2026 |
| revenue | FY2026 | $602.00M – $610.00M | $600.00M – $610.00M | Raised | Jul 23, 2026 |
| revenue | FY2026 | $600.00M – $610.00M | – | New | Feb 17, 2026 |
| revenue growth | FY2026 | +12% – +14% | – | New | Jan 12, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $91.00M – $94.00M | $80.00M – $82.00M | Raised | Nov 3, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $85.00M – $89.00M | $80.00M – $82.00M | Raised | Jul 23, 2026 |
| net income per shareGAAP | FY2026 | $0.21 – $0.27 | $0.00 – $0.04 | Raised | Nov 3, 2026 |
| net income per shareGAAP | FY2026 | $0.05 – $0.13 | – | New | Jul 23, 2026 |
| adjusted earnings per sharenon-GAAP | FY2026 | $0.40 – $0.46 | $0.09 – $0.15 | Raised | Nov 3, 2026 |
| adjusted earnings per sharenon-GAAP | FY2026 | $0.24 – $0.32 | $0.00 – $0.04 | Raised | Jul 23, 2026 |
Guidance vs results
The last range AtriCure gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | adjusted loss per share | -$0.26 – -$0.23 | -$0.11Σ4Q | Above range |
| FY2025 | Revenue | $532.00M – $534.00M | $534.50MΣ4Q | Above range |
Guidance history
Every forecast AtriCure put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 3, 2026 | adjusted EBITDA | FY2026 | $91.00M – $94.00M | Raised |
| Nov 3, 2026 | adjusted earnings per share | FY2026 | $0.40 – $0.46 | Raised |
| Nov 3, 2026 | net income per share | FY2026 | $0.21 – $0.27 | Raised |
| Nov 3, 2026 | revenue | FY2026 | $606.00M – $610.00M | New |
| Jul 23, 2026 | adjusted EBITDA | FY2026 | $85.00M – $89.00M | Raised |
| Jul 23, 2026 | adjusted earnings per share | FY2026 | $0.24 – $0.32 | Raised |
| Jul 23, 2026 | net income per share | FY2026 | $0.05 – $0.13 | New |
| Jul 23, 2026 | revenue | FY2026 | $602.00M – $610.00M | Raised |
| May 5, 2026 | Adjusted EBITDA | FY2026 | $80.00M – $82.00M | Reaffirmed |
| May 5, 2026 | adjusted earnings per share | FY2026 | $0.00 – $0.04 | New |
| May 5, 2026 | revenue | FY2026 | $600.00M – $610.00M | Reaffirmed |
| Feb 17, 2026 | adjusted EBITDA | FY2026 | $80.00M – $82.00M | New |
| Feb 17, 2026 | adjusted earnings per share | FY2026 | $0.09 – $0.15 | New |
| Feb 17, 2026 | net earnings per share | FY2026 | $0.00 – $0.04 | New |
| Feb 17, 2026 | revenue | FY2026 | $600.00M – $610.00M | New |
| Jan 12, 2026 | adjusted EBITDA | FY2026 | $80.00M – $82.00M | New |
| Jan 12, 2026 | revenue growth | FY2026 | +12% – +14% | New |
| Jan 12, 2026 | revenue | FY2026 | $600.00M – $610.00M | New |
| Oct 29, 2025 | Adjusted EBITDA | FY2025 | $55.00M – $57.00M | New |
| Oct 29, 2025 | adjusted loss per share | FY2025 | -$0.26 – -$0.23 | New |
| Oct 29, 2025 | revenue | FY2025 | $532.00M – $534.00M | New |
| Jul 29, 2025 | Adjusted EBITDA | FY2025 | $49.00M – $52.00M | Raised |
| Jul 29, 2025 | adjusted loss per share | FY2025 | -$0.39 – -$0.34 | Raised |
| Jul 29, 2025 | revenue | FY2025 | $527.00M – $533.00M | Raised |
| Apr 29, 2025 | Adjusted EBITDA | FY2025 | $44.00M – $46.00M | Raised |
| Apr 29, 2025 | adjusted loss per share | FY2025 | -$0.55 – -$0.50 | Lowered |
| Apr 29, 2025 | revenue | FY2025 | $517.00M – $527.00M | Reaffirmed |
| Feb 12, 2025 | adjusted EBITDA | FY2025 | $42.00M – $44.00M | Raised |
| Feb 12, 2025 | adjusted loss per share | FY2025 | $0.57 – $0.64 | New |
| Feb 12, 2025 | revenue | FY2025 | $517.00M – $527.00M | Reaffirmed |
| Jan 13, 2025 | adjusted EBITDA | FY2025 | $40.00M – $44.00M | New |
| Jan 13, 2025 | revenue | FY2025 | $517.00M – $527.00M | New |
| Oct 29, 2024 | adjusted EBITDA represents a 34% to 49% increase over full year 2023 | FY2024 | +34% – +49% | New |
| Oct 29, 2024 | Adjusted EBITDA | FY2024 | $26.00M – $29.00M | Reaffirmed |
| Oct 29, 2024 | adjusted loss per share | FY2024 | -$0.80 – -$0.74 | Lowered |
| Oct 29, 2024 | growth | FY2024 | +15% – +16% | New |
| Oct 29, 2024 | revenue | FY2024 | $459.00M – $462.00M | Lowered |
| Jul 30, 2024 | Adjusted EBITDA | FY2024 | $26.00M – $29.00M | Reaffirmed |
| Jul 30, 2024 | adjusted loss per share | FY2024 | $0.74 – $0.82 | Reaffirmed |
| Jul 30, 2024 | revenue | FY2024 | $456.00M – $461.00M | Lowered |
| May 1, 2024 | Adjusted EBITDA | FY2024 | $26.00M – $29.00M | Reaffirmed |
| May 1, 2024 | adjusted loss per share | FY2024 | $0.74 – $0.82 | Reaffirmed |
| May 1, 2024 | revenue | FY2024 | $459.00M – $466.00M | New |
| Feb 15, 2024 | adjusted EBITDA | FY2024 | $26.00M – $29.00M | Reaffirmed |
| Feb 15, 2024 | adjusted loss per share | FY2024 | $0.74 – $0.82 | New |
| Feb 15, 2024 | revenue | FY2024 | $459.00M – $466.00M | Reaffirmed |
| Jan 8, 2024 | positive adjusted EBITDA | FY2024 | $26.00M – $29.00M | New |
| Jan 8, 2024 | revenue | FY2024 | $459.00M – $466.00M | New |
| Nov 1, 2023 | adjusted EBITDA | FY2023 | $18.00M – $20.00M | Raised |
| Nov 1, 2023 | adjusted loss per share | FY2023 | $0.74 – $0.76 | Lowered |
| Nov 1, 2023 | revenue | FY2023 | $394.00M – $396.00M | Raised |
| Jul 25, 2023 | adjusted EBITDA | FY2023 | $12.00M | Raised |
| Jul 25, 2023 | adjusted loss per share | FY2023 | $0.92 – $0.94 | Lowered |
| Jul 25, 2023 | revenue | FY2023 | $392.00M – $395.00M | Raised |
| May 2, 2023 | adjusted EBITDA | FY2023 | $2.00M | New |
| May 2, 2023 | adjusted loss per share | FY2023 | $1.10 – $1.15 | Lowered |
| May 2, 2023 | revenue | FY2023 | $385.00M – $392.00M | Raised |
| Feb 21, 2023 | adjusted loss per share | FY2023 | $1.14 – $1.19 | New |
| Feb 21, 2023 | revenue | FY2023 | $380.00M – $387.00M | New |
| Jan 9, 2023 | revenue | FY2023 | $380.00M – $387.00M | New |
| Nov 1, 2022 | adjusted EBITDA | FY2022 | $4.00M | Raised |
| Nov 1, 2022 | adjusted loss per share | FY2022 | $1.10 – $1.12 | Raised |
| Nov 1, 2022 | revenue | FY2022 | $328.00M – $333.00M | Raised |
| Aug 2, 2022 | adjusted EBITDA | FY2022 | $2.00M – $4.00M | Reaffirmed |
| Aug 2, 2022 | adjusted loss per share | FY2022 | $1.07 – $1.12 | Reaffirmed |
| Aug 2, 2022 | revenue | FY2022 | $323.00M – $333.00M | Raised |
| May 3, 2022 | adjusted EBITDA | FY2022 | $2.00M – $4.00M | Reaffirmed |
| May 3, 2022 | adjusted loss per share | FY2022 | $1.07 – $1.12 | Reaffirmed |
| May 3, 2022 | revenue | FY2022 | $318.00M – $330.00M | Raised |
| Feb 15, 2022 | adjusted EBITDA | FY2022 | $2.00M – $4.00M | New |
| Feb 15, 2022 | adjusted loss per share | FY2022 | $1.07 – $1.12 | New |
| Feb 15, 2022 | revenue | FY2022 | $315.00M – $330.00M | Reaffirmed |
| Jan 10, 2022 | revenue | FY2022 | $315.00M – $330.00M | New |
| Nov 3, 2021 | adjusted EBITDA loss | FY2021 | $10.00M | New |
| Nov 3, 2021 | adjusted loss per share | FY2021 | $1.20 | New |
| Nov 3, 2021 | revenue | FY2021 | $270.00M – $275.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases AtriCure filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
See a number that looks wrong?